FDA Approved: DYANAVEL XR — Supplemental Application (NextWave Pharmaceuticals, Inc)

View source ↗

Summary

FDA approved a supplemental application for DYANAVEL XR (amphetamine) submitted by NextWave Pharmaceuticals, Inc. The submission status is AP.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Dyanavel XR (amphetamine (extended-release))

Snippet

SUPPL AP for DYANAVEL XR (AMPHETAMINE)